ArticleThe Journal of allergy and clinical immunology2025
Fine resolution of the N-terminal IgE-binding epitope of Ara h 2: Discovery of variants with enhanced IgE binding.
Article in The Journal of allergy and clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immunization with Virus-Like Particles Displaying Ara h 2‑Derived Peptides to Mitigate Peanut Allergy.ACS nano medicine · 2026Article
- IgE Anti-Beta Coronaviruses Serology in Napoleon Soldiers, France.Journal of medical virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundIgE binding to linear peptides from the N-terminal region of Ara h 2 (epitope 1) is associated with the achievement of sustained unresponsiveness in young children receiving oral immunotherapy and may be important for cross-reactivity between peanuts and tree nuts. This region is also part of the binding site for neutralizing IgG monoclonal antibodies associated with sustained unresponsiveness following oral immunotherapy.
objectiveWe sought to perform alanine scanning of this epitope to determine the importance of individual amino acids and then amino acid scanning to screen for sequences with enhanced binding of IgE.
methodsA streptavidin IgE ELISA with biotinylated peptides was used to measure the binding of IgE to full-length and truncated peptides to identify a core sequence (DRRCQSQLERAN, amino acids 30-41 in the Ara h 2 sequence). Peptide microarrays were used to screen multiple peptides and quantitate binding of IgE. Statistical analysis included one-way ANOVA followed by the Dunnett multiple comparison test.
resultsIgE binding was greatly reduced when alanine was substituted for arginine at positions 31, 32, and 39 (R31, P < .001; R32, P < .01; R39, P < .001); glutamine at positions 34 and 36 (Q34, P < .01; Q36, P < .001); and glutamate at position 38 (E38, P < .01). Substitution of aspartate with asparagine at position D30 in conjunction with substitution of asparagine at position N41 with either leucine or lysine gave enhanced binding (P < .0001). Molecular modeling of these data suggests a conformational basis for recognition by polyclonal IgE.
conclusionsIgE binding assays using pooled and individual sera demonstrated the importance of amino acids throughout the sequence of epitope 1 for immune recognition. The results of alanine scanning indicated residues that could be changed as part of a larger strategy to generate hypoallergenic forms of Ara h 2, whereas sequence variants with enhanced binding were identified that may be useful for improving diagnostics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.